Literature DB >> 10780732

Phenotypic resistance to protease inhibitors in patients who fail on highly active antiretroviral therapy predicts the outcome at 48 weeks of a five-drug combination including ritonavir, saquinavir and efavirenz.

C Piketty, E Race, P Castiel, L Belec, G Peytavin, A Si-Mohamed, G Gonzalez-Canali, L Weiss, F Clavel, M D Kazatchkine.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10780732     DOI: 10.1097/00002030-200003310-00025

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  3 in total

Review 1.  Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.

Authors:  D P Figgitt; G L Plosker
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

Review 2.  Saquinavir: a review of its use in boosted regimens for treating HIV infection.

Authors:  Greg L Plosker; Lesley J Scott
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Potential Hepatotoxicity of Efavirenz and Saquinavir/Ritonavir Coadministration in Healthy Volunteers.

Authors:  Candice Jamois; Myriam Riek; Christophe Schmitt
Journal:  Arch Drug Inf       Date:  2009-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.